Milestone Pharmaceuticals (MIST) Research & Development (2018 - 2022)

Milestone Pharmaceuticals (MIST) has reported Research & Development for 5 consecutive years, with $9.8 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Research & Development rose 0.96% year-over-year to $9.8 million; the trailing twelve-month figure through Sep 2022 stood at $41.1 million (up 22.71% YoY), and the FY2021 full-year result was $38.7 million, up 12.13% from the prior year.
• Research & Development eased to $9.8 million in Q3 2022 per MIST's latest filing, from $10.7 million in the prior quarter.
• Across five years, Research & Development topped out at $14.1 million in Q4 2019 and bottomed at $2.6 million in Q2 2018.
• Historically, Research & Development has averaged $8.5 million across 5 years, with a median of $9.0 million in 2020.
• The sharpest annual moves came in 2019 and 2020: Research & Development jumped 312.66% in 2019, then sank 59.25% in 2020.
• Over 5 years, Research & Development stood at $7.3 million in 2018, then surged by 93.9% to $14.1 million in 2019, then tumbled by 59.25% to $5.8 million in 2020, then surged by 89.32% to $10.9 million in 2021, then retreated by 9.99% to $9.8 million in 2022.
• According to Business Quant data, Research & Development over the past three periods registered $9.8 million, $10.7 million, and $10.9 million for Q3 2022, Q2 2022, and Q4 2021 respectively.